[1]
J. H. Hoffmann, C. Knoop, A. H. Enk, and E. N. Hadaschik, “Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab”, Acta Derm Venereol, vol. 97, no. 6, pp. 705–710, Mar. 2017.